Episode 32: Fake friends at the FDA, cancer counter-narratives, and biotech's bear turn
Is the next big idea in oncology a bust? What does "successful" mean exactly? And why does Wall Street hate biotech all of a sudden?
11 Loka 201822min
Episode 31: Nobel snubs, millenial founders, and a new kind of lightning round
Did the Nobel Prizes go to the right scientists? Why is there so much disdain for biotech's millenial entrepreneurs? And do journalists have a good taste in '80s music?
4 Loka 201823min
Episode 30: A fish oil epiphany, VC monopolies and ketamine clinics
Was everyone wrong about fish oil? Is venture capital a cartel? And what's with all those ketamine clinics?
27 Syys 201825min
Episode 29: A Hong Kong heat-check, a $20 million wrist slap, and pharma's (other) diversity problem
Is a biotech bubble inflating in China? Do the feds coddle CEOs? And why don't clinical trials look like America?
20 Syys 201824min
Episode 28: Founders' funds, doctors' disclosures, and the subtle art of beeping
Is biotech too founder-friendly? Is honesty overrated? And how do you tell a good beep from a bad one?
13 Syys 201822min
Episode 27: Live from Boston!
Should genome editors be worried? Has 2018 been a bummer? And are voters ready to love Big Pharma? We discuss this and more on a special live episode from the BioPharm America conference in Boston.
6 Syys 201826min
Episode 26: FDA shows its teeth, biotech fish oil might be pointless, & treating McCain's cancer
Is the FDA as lenient as everyone thinks? Can fish oil be a multibillion-dollar drug? And why aren't there better treatments for brain cancer?
30 Elo 201817min
Episode 25: A genome-editing first, Trump on Wall Street, and biotech red flags
Can genome-editing work in actual people? Are CEOs oversharing? And how do you sniff out a bad bet before it happens?
23 Elo 201821min
